Please login to the form below

Not currently logged in
Email:
Password:

Experts back sanofi-aventis' Lantus

Sanofi-aventis has published a statement from a panel of experts stating there is no established cancer risk linked to the use of the insulin Lantus

Sanofi-aventis has published a statement from a panel of experts stating there is no established cancer risk linked to the use of the insulin Lantus (glargine).

Following the publication of four epidemiological studies, drawing attention to the link between obesity, diabetes and cancer in the journal Diabetologia, sanofi-aventis assembled a board of international specialists in the field of endocrinology, oncology and epidemiology.

The board concluded that the four manuscripts had significant methodological limitations and shortcomings and provided inconsistent and inconclusive results over a potential link between using glargine and an increased risk of cancer.

When the reports were first published in the journal, shares in sanofi-aventis fell.

The European Medicines Agency (EMEA) has launched an investigation into the information published in Diabetologia. Based on the data available, the EMEA was unable to establish a link between Lantus and cancer but stated that studies required in-depth evaluation.

Results of a five-year study of Lantus versus NPH insulin on progression of retinopathy in patients with type 2 diabetes carried out by the French pharmaceutical company showed no retinopathy progression risk

Lantus is a key product for sanofi-aventis and, in 2008, generated sales of €2.6bn.

16th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics